---
title: "Immuneering Corp. Reports Promising Cancer Trial Results"
description: "Immuneering Corp. (IMRX) reported promising results from its Phase 2a trial of IMM-1-104 for pancreatic cancer, showing encouraging response rates when combined with chemotherapy. The company also ann"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/232811961.md"
published_at: "2025-03-22T03:51:04.000Z"
---

# Immuneering Corp. Reports Promising Cancer Trial Results

> Immuneering Corp. (IMRX) reported promising results from its Phase 2a trial of IMM-1-104 for pancreatic cancer, showing encouraging response rates when combined with chemotherapy. The company also announced a collaboration with Regeneron Pharmaceuticals to evaluate IMM-1-104 with Libtayo for non-small cell lung cancer. Despite a net loss for 2024 due to increased R&D expenses, Immuneering has extended its cash runway into 2026, supporting future trials and data updates planned for 2025.

Immuneering Corp. Class A ( (IMRX) ) has released its Q4 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented to its investors.

Immuneering Corporation, a clinical-stage oncology company, is focused on developing therapies for cancer patients, with a lead product candidate, IMM-1-104, targeting RAS-driven tumors. In its latest earnings report, Immuneering shared promising updates from its Phase 2a trial of IMM-1-104, showing encouraging response rates in pancreatic cancer patients when combined with chemotherapy. The company also announced a collaboration with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo for non-small cell lung cancer. Financially, Immuneering reported a net loss for 2024, with increased research and development expenses attributed to its ongoing clinical trials. Despite the losses, the company has extended its cash runway into 2026, indicating a stable financial position to support its future plans. Looking ahead, Immuneering is preparing for additional trials and data updates in 2025, aiming to advance its pipeline and potentially offer improved treatment options for cancer patients.

## Trending Articles:

-   Paramount Stock (NASDAQ:PARA) Dips as it Pulls CBS Mornings out of Times Square
-   Ford Stock (NYSE:F) Notches Up With Ford Digital Experience Change
-   Intel Stock (NASDAQ:INTC) Gains on Work With “Mission-Critical Systems”

Questions or Comments about the article? Write to editor@tipranks.com

### Related Stocks

- [IMRX.US - Immuneering](https://longbridge.com/en/quote/IMRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immuneering 公布了强劲的 2a 期胰腺癌生存数据 | Immuneering (IMRX) 报告了其针对胰腺癌的 2a 期临床试验的有希望的中期结果，显示 12 个月的总体生存率为 64%，而标准治疗为 35%。该治疗耐受性良好，没有严重不良事件。Immuneering 计划推进 3 期临床试 | [Link](https://longbridge.com/en/news/271839962.md) |
| Immuneering 内部人士对公司未来做出了大胆的新赌注 | Immuneering (IMRX) 的内部活动显示，董事彼得·费因伯格购买了 20,000 股，花费 86,800 美元，表明他对公司未来的信心。尽管最近股价下跌了 40%，降至 4.96 美元，但关于 atebimetinib 在胰腺癌 | [Link](https://longbridge.com/en/news/272634480.md) |
| NCCN 发布的新指南详细阐述了儿童癌症与成人癌症之间的基本差异 | 国家综合癌症网络（NCCN）发布了针对儿童软组织肉瘤的新临床实践指南，重点关注横纹肌肉瘤（RMS），这是儿童中最常见的软组织肉瘤。这些指南提供了基于证据的诊断、治疗和风险分层建议，强调了儿童癌症与成人癌症之间的差异。其目的是确保有效治疗的同 | [Link](https://longbridge.com/en/news/276145789.md) |
| 癌症与血液疾病中心为德克萨斯州患者革新了 CAR-T 癌症治疗的提供方式 | 癌症与血液疾病中心已启动一项计划，在德克萨斯州的社区医疗机构提供 CAR-T 疗法，显著扩大患者对这一先进癌症治疗的获取。该中心与当地医院合作，正在治疗首位患者，一名 62 岁的 B 细胞淋巴瘤男性患者。此项举措是在德克萨斯州通过 3057 | [Link](https://longbridge.com/en/news/276139832.md) |
| AgelessRx 在癌症预防月期间扩大了多癌症早期检测解决方案的可及性 | AgelessRx 正在扩大其多癌种早期检测解决方案的可及性，以纪念癌症预防月。该倡议旨在增强筛查工具的可用性，以便在早期阶段识别潜在的癌症信号。该公司正在优化其流程，以便更好地提供这些解决方案，这些方案分析血液样本中与多种癌症类型相关的生 | [Link](https://longbridge.com/en/news/276180967.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.